255 related articles for article (PubMed ID: 19751153)
1. Cost-effectiveness of a potential prophylactic Helicobacter pylori vaccine in the United States.
Rupnow MF; Chang AH; Shachter RD; Owens DK; Parsonnet J
J Infect Dis; 2009 Oct; 200(8):1311-7. PubMed ID: 19751153
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of a potential future Helicobacter pylori vaccine in the Netherlands: the impact of varying the discount rate for health.
de Vries R; Klok RM; Brouwers JR; Postma MJ
Vaccine; 2009 Feb; 27(6):846-52. PubMed ID: 19084566
[TBL] [Abstract][Full Text] [Related]
3. New vaccines against otitis media: projected benefits and cost-effectiveness.
O'Brien MA; Prosser LA; Paradise JL; Ray GT; Kulldorff M; Kurs-Lasky M; Hinrichsen VL; Mehta J; Colborn DK; Lieu TA
Pediatrics; 2009 Jun; 123(6):1452-63. PubMed ID: 19482754
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness analysis between primary and secondary preventive strategies for gastric cancer.
Lee YC; Lin JT; Wu HM; Liu TY; Yen MF; Chiu HM; Wang HP; Wu MS; Hsiu-Hsi Chen T
Cancer Epidemiol Biomarkers Prev; 2007 May; 16(5):875-85. PubMed ID: 17507609
[TBL] [Abstract][Full Text] [Related]
5. Helicobacter pylori vaccine development and use: a cost-effectiveness analysis using the Institute of Medicine Methodology.
Rupnow MF; Owens DK; Shachter R; Parsonnet J
Helicobacter; 1999 Dec; 4(4):272-80. PubMed ID: 10597398
[TBL] [Abstract][Full Text] [Related]
6. The cost-effectiveness of routine office-based identification and subsequent medical treatment of primary open-angle glaucoma in the United States.
Rein DB; Wittenborn JS; Lee PP; Wirth KE; Sorensen SW; Hoerger TJ; Saaddine JB
Ophthalmology; 2009 May; 116(5):823-32. PubMed ID: 19285730
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of influenza vaccination in working-age cancer patients.
Avritscher EB; Cooksley CD; Geraci JM; Bekele BN; Cantor SB; Rolston KV; Elting LS
Cancer; 2007 Jun; 109(11):2357-64. PubMed ID: 17457827
[TBL] [Abstract][Full Text] [Related]
8. [The cost-effectiveness of pneumococcal vaccination in Catalonia].
Plans Rubió P; Garrido Morales P; Salleras Sanmartí L
Rev Esp Salud Publica; 1995; 69(5):409-17. PubMed ID: 8564860
[TBL] [Abstract][Full Text] [Related]
9. Retrospective cost-effectiveness analyses for polio vaccination in the United States.
Thompson KM; Tebbens RJ
Risk Anal; 2006 Dec; 26(6):1423-40. PubMed ID: 17184390
[TBL] [Abstract][Full Text] [Related]
10. [Cost-effectiveness of Helicobacter pylori screening to prevent gastric cancer: Markov decision analysis].
Wang Q; Jin PH; Lin GW; Xu SR; Chen J
Zhonghua Liu Xing Bing Xue Za Zhi; 2003 Feb; 24(2):135-9. PubMed ID: 12697117
[TBL] [Abstract][Full Text] [Related]
11. Illustrating economic evaluation of diagnostic technologies: comparing Helicobacter pylori screening strategies in prevention of gastric cancer in Canada.
Xie F; O'Reilly D; Ferrusi IL; Blackhouse G; Bowen JM; Tarride JE; Goeree R
J Am Coll Radiol; 2009 May; 6(5):317-23. PubMed ID: 19394572
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of the pneumococcal vaccine in the United States Navy and Marine Corps.
Vold Pepper P; Owens DK
Clin Infect Dis; 2000 Jan; 30(1):157-64. PubMed ID: 10619745
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness analysis of Helicobacter pylori screening in prevention of gastric cancer in Chinese.
Xie F; Luo N; Blackhouse G; Goeree R; Lee HP
Int J Technol Assess Health Care; 2008; 24(1):87-95. PubMed ID: 18218173
[TBL] [Abstract][Full Text] [Related]
14. Helicobacter pylori vaccine development: optimisation of strategies and importance of challenging strain and animal model.
Hoffelner H; Rieder G; Haas R
Int J Med Microbiol; 2008 Jan; 298(1-2):151-9. PubMed ID: 17714988
[TBL] [Abstract][Full Text] [Related]
15. Towards the development of vaccines against Helicobacter pylori: status and issues.
Del Giudice G
Curr Opin Investig Drugs; 2001 Jan; 2(1):40-4. PubMed ID: 11527009
[TBL] [Abstract][Full Text] [Related]
16. Vaccinating adolescents against meningococcal disease in Canada: a cost-effectiveness analysis.
De Wals P; Coudeville L; Trottier P; Chevat C; Erickson LJ; Nguyen VH
Vaccine; 2007 Jul; 25(29):5433-40. PubMed ID: 17560695
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of live attenuated influenza vaccine versus inactivated influenza vaccine among children aged 24-59 months in the United States.
Luce BR; Nichol KL; Belshe RB; Frick KD; Li SX; Boscoe A; Rousculp MD; Mahadevia PJ
Vaccine; 2008 Jun; 26(23):2841-8. PubMed ID: 18462851
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of routine childhood vaccination for hepatitis A in the United States.
Rein DB; Hicks KA; Wirth KE; Billah K; Finelli L; Fiore AE; Hoerger TJ; Bell BP; Armstrong GL
Pediatrics; 2007 Jan; 119(1):e12-21. PubMed ID: 17200237
[TBL] [Abstract][Full Text] [Related]
19. Systemic immunization with unadjuvanted whole Helicobacter pylori protects mice against heterologous challenge.
Harbour SN; Every AL; Edwards S; Sutton P
Helicobacter; 2008 Dec; 13(6):494-9. PubMed ID: 19166414
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness of vaccination with recombinant HpaA from Helicobacter pylori is influenced by host genetic background.
Sutton P; Doidge C; Pinczower G; Wilson J; Harbour S; Swierczak A; Lee A
FEMS Immunol Med Microbiol; 2007 Jul; 50(2):213-9. PubMed ID: 17567282
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
